-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Studies have shown that dihydropyridine calcium channel blockers may be associated with a reduced risk of Parkinson's disease (PD).
The 57 Parkinson’s research team sites in North America included patients with early Parkinson’s disease (duration <3 years) who were not taking dopaminergic drugs at the time of enrollment and were randomized to receive 5 mg promethazine or placebo twice a day.
A total of 336 patients were randomized (mean age 62 years [SD, 9]; 68% were male; disease duration 0.
After adjusting the average of least squares, the total UPDRS score changes of promethazine and placebo recipients under the anti-Parkinson drug ON state within 36 months were 2.
In summary, the results of this study show that long-term use of fast-acting promethazine cannot slow down the clinical progression of early PD.
Original source:
Parkinson Study Group STEADY-PD III Investigators.
Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial
in this message